Navigation Links
Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
Date:6/28/2011

EXTON, Pa., June 28, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center phase II study of farletuzumab in adenocarcinoma of the lung, a type of non-small cell lung cancer (NSCLC). The study will evaluate farletuzumab, a monoclonal antibody that specifically binds to folate receptor-alpha (FRA), with the physician's choice of one of three standard platinum-containing doublets that are approved and recommended for first-line metastatic lung cancer patients.

The trial is designed as a randomized, double-blind, placebo-controlled study to determine if  farletuzumab delays the time to tumor progression when it is added to one of the standard-of-care chemotherapy options for metastatic adenocarcinoma of the lung. Secondary objectives include safety, response rate and duration of response, and overall survival benefit of patients treated with the antibody plus chemotherapy versus the chemotherapy with a placebo. The patient population includes individuals with advanced NSCLC adenocarcinoma who have tumors that over-express FRA and have not received any prior radiation or chemotherapy for curative intent of their disease. It is estimated that about three-quarters of adenocarcinoma of the lung are FRA-positive.

Morphotek expects to enroll up to 120 patients in this clinical study, which is being conducted at clinical centers globally.  As part of the study, a Morphotek-developed diagnostic kit will be used to determine patient eligibility.  

"We are excited to have initiated this global phase II study of farletuzumab in cooperation with leading physicians.  Since farletuzumab targets FRA, this personalized approach will include only those patients who could potentially benefit from therapy with the new agent," stated Julia Maltzman, M.D., Senior Director of Clinical Development at Morphotek. "NSCLC has a generally poor prognosis, so we hope that farletuzumab
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader in ... its 2010 year-end results for the 12 months ended ... Commission on Wednesday, March 30, 2011. Milestone,s ... 4, 2011 beginning at 4:15 PM Eastern Daylight Savings ...
... YORK, April 1, 2011 NeoStem, Inc. (NYSE Amex: ... company with operations in the U.S. and China, is today ... activities: Revenues for the year ended December ... 2009.  2010 was the first full year that results for ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2NeoStem Provides Results for 2010 and an Update on Recent Activities 2NeoStem Provides Results for 2010 and an Update on Recent Activities 3NeoStem Provides Results for 2010 and an Update on Recent Activities 4NeoStem Provides Results for 2010 and an Update on Recent Activities 5
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... Viejo, CA (PRWEB) May 24, 2015 ProPin ... use in Final Cut Pro X. Utilize ProPin to pin ... in a given scene. , ProPin allows users to ... completely customizable in FCPX. With on-screen controls, video editors can ... allows users to pin and mark with absolute ease. , Using ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Krihak as its head of programmatic strategy and ... expertise and leadership position in the data driven ... , Krihak is an experienced, award-winning agency and ... sales planning teams for mobile platform Jumptap. ...
(Date:5/24/2015)... 24, 2015 A report out ... the single best option for avoiding cardiovascular disease is ... level was the single most powerful predictor of death ... as diabetes and family history of premature death -- ... heart and lung fitness. , The Importance of Cardiovascular ...
(Date:5/23/2015)... D.C. (PRWEB) May 23, 2015 On ... of powers of a youngster's yogic power learned through ... Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, a ... more than 50 high profile professionals attending the 2015 ... by reading fluently -- blindfolded. , In a ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... 2009, Cambridge, UK ,Anyone with a sweet tooth knows ... negative consequences. The same can be said about the ... new study of myelin, a protein key to efficient neuronal ... much like the insulation on a cable, allows for rapid ...
... nanospheres equipped with a targeting peptide find melanoma cells, penetrate ... near-infrared light, a research team led by scientists at The ... the Feb. 1 issue of Clinical Cancer Research . ... grail of therapeutic nanotechnology for cancer. We,re getting closer to ...
... Knowing what to expect before and after procedure aids healing, ... With increasing numbers of baby boomers reaching retirement age, joint ... , But improved movement and lack of pain in ... to expect from the surgery and subsequent physical therapy can ...
... Total Health Center shows that our new Hgh product destroys fat cells ... , ... (PRWEB) February 1, 2009 -- Scientists at The Total Health and ... to destroy fat on men and women without dieting. Sources at the ...
... A study in the Feb. 1 issue of the ... levels that occurs during pregnancy is more pronounced in pregnant ... , During the last trimester of pregnancy, levels ... women with RLS and 25,475 pg/mL in healthy controls. ...
... A study in the Feb. 1 issue of the ... associated with changes in the levels of specific cytokines ... suggest that inflammation may be the pathway linking extreme ... Each additional hour of self-reported sleep duration was associated ...
Cached Medicine News:Health News:Targeted nanospheres find, penetrate, then fuel burning of melanoma 2Health News:Targeted nanospheres find, penetrate, then fuel burning of melanoma 3Health News:A Checklist for Joint Replacement Surgery 2Health News:Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome 2Health News:Study suggests that inflammation may be the link between extreme sleep durations and poor health 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: